Compare Global E Online Ltd (GLBE) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Global E Online Ltd trades at $38.28 (market cap $6.55B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Global E Online Ltd is far larger — about 6.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Global E Online Ltd is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GLBE | MRVI | |
|---|---|---|
Market Cap | $6.55B | $972.90M |
Volume | 1,171,020 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $9.00 |
52-Week Low | $27.54 | $2.83 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $6.05B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $39.00, down 0.05% with a bearish technical signal. The company shows strong fundamentals with Q2 2026 earnings beating expectations and revenue growth accelerating to 39% year-over-year. Analyst sentiment remains overwhelmingly positive with 93% buy ratings and a $48.86 consensus price target representing 25% upside potential. Recent executive appointments and strong Q2 results have driven positive momentum, though insider selling activity warrants monitoring.
The outlook remains favorable with projected revenue growth to $1.1B in 2026 and expanding profit margins. Key risks include competitive pressures in e-commerce enablement and potential market volatility. The stock's current valuation at 44.32 P/E reflects growth expectations, with technical resistance at $40 needing to be overcome for further upside.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
